GlassScriptPhysician profile
Sara W Starks
NPI 1356831655
$4,124.33
in general payments reported to CMS, 2019-2025
25 companies · $2,788 in 2025
The $2,788 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,337 · 2025: $2,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,124.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $920.52 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $524.81 | 2024-2025 | Tezspire, Tavneos |
| Genzyme Corporation | $310.15 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $296.68 | 2024-2025 | Fasenra, Breztri, Tezspire |
| Insmed, INC. | $266.73 | 2024-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $237.29 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $221.74 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $206.33 | 2025 | Yupelri |
| Mylan Specialty L.P. | $193.20 | 2024 | Yupelri |
| Pulmonx Corporation | $129.71 | 2024-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Grifols USA, LLC | $112.91 | 2024-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.15 | 2024-2025 | Ofev |
| United Therapeutics Corporation | $101.73 | 2024-2025 | Tyvaso, Tyvaso |
| Csl Behring | $91.47 | 2024-2025 | Kcentra |
| Merck Sharp & Dohme LLC | $68.02 | 2024-2025 | Zerbaxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $56.73 | 2025 | Zemaira |
| Actelion Pharmaceuticals US, INC. | $52.41 | 2025 | Opsumit, Uptravi, Opsynvi |
| Axsome Therapeutics, INC. | $46.78 | 2024-2025 | Sunosi |
| Philips North America LLC | $38.02 | 2025 | Vest Therapy Und |
| Harmony Biosciences LLC | $36.91 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.21 | 2025 | Glassia, Aralast |
| Lilly USA, LLC | $19.83 | 2025 | Zepbound |
| Inogen, INC. | $16.61 | 2025 | |
| Electromed, INC. | $16.41 | 2025 | Smartvest |
| Genentech USA, INC. | $13.98 | 2024 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Starks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.